MarketFriction

Neuland Laboratories Ltd

NSE NEULANDLAB · BSE 524558 · Pharmaceuticals
₹21,505.00 +0.73%
NSE close2026-10-01
52 week range11,500.00 - 24,225.00
Market cap₹27,424 Cr.
P/E55.1
Nifty 500Nifty Smallcap 50Nifty Smallcap 100Smallcap 250 Price band 20% Delivery 54.0%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales418393385440311398328293514440776642
Expenses280272278316249311277258359363469419
Operating Profit1371211071236287513415677307223
OPM %33%31%28%28%20%22%16%12%30%18%40%35%
Other Income325254607828128
Interest444312255777
Depreciation151516161616172023242527
Profit before tax1221049213049128391812954287198
Tax %27%22%27%25%34%20%29%21%25%26%26%25%
Net Profit898168983310228149741213148
EPS in Rs69.5663.4452.6676.2825.6079.1821.6810.8375.4931.62165.76115.10
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales5105795276677639379511,1911,5591,4772,0232,372
Expenses4304724776086617908079181,0961,1461,4431,609
Operating Profit801065158102147144273463331580763
OPM %16%18%10%9%13%16%15%23%30%22%29%32%
Other Income21434160912902531
Interest24211916221814131482426
Depreciation161922263140495360669298
Profit before tax426714205310582216401346489669
Tax %36%30%13%19%69%23%22%24%25%25%26%
Net Profit27471216168164164300260364498
EPS in Rs30.7552.7413.5712.8112.6362.8549.74127.45233.89202.74283.71387.97
Dividend Payout %7%0%0%0%16%8%10%8%6%6%12%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth15%17%19%78%
Compounded Profit Growth29%39%30%278%
Stock Price CAGR36%70%80%46%
Return on Equity14%18%20%21%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital99991313131313131313
Reserves1521785375496866977748289811,2701,5121,862
Borrowings18818219231923126418224112895157301
Other Liabilities162155148194200257356302457454498754
Total Liabilities5125248861,0711,1301,2311,3251,3831,5801,8332,1802,930
Fixed Assets1231394664755426537167677588249551,177
CWIP414020126104241720414648211
Investments77888874111092
Other Assets3403373934634765475855927819621,0681,541
Total Assets5125248861,0711,1301,2311,3251,3831,5801,8332,1802,930
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity13453911705718960237261317347
Cash from Investing Activity-14-20-42-116-77-49-84-95-61-150-298-423
Cash from Financing Activity1-24-010512-5-11438-136-692521
Net Cash Flow01-4-053-93404244-55
Free Cash Flow-126-2-1217984-37173119112-50
CFO/OP33%70%52%28%128%61%132%56%103%81%119%78%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1008511413490918590111877898
Inventory Days170182186266191209205227211220238245
Days Payable167121118189118110126100129121156129
Cash Conversion Cycle103147182211162190164216193187160214
Working Capital Days11264438138137607481887675
ROCE %16%18%16%4%4%8%11%10%21%33%19%26%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters35.97%32.80%32.74%32.72%32.64%32.68%32.67%32.67%32.64%32.63%32.63%32.62%
FIIs21.57%22.69%24.43%25.72%26.46%23.86%22.12%21.69%20.60%20.90%20.46%21.08%
DIIs6.99%6.02%6.54%6.39%6.38%9.09%10.97%11.57%13.55%14.72%15.84%16.52%
Government0.40%0.40%0.40%0.40%0.40%0.40%0.40%0.40%0.40%0.00%0.00%0.00%
Public35.08%38.10%35.88%34.77%34.12%33.96%33.85%33.67%32.80%31.76%31.08%29.79%
No. of Shareholders26,82427,72328,61629,07734,56739,31539,33342,41944,39346,18746,30444,340

Fundamentals

Market Cap₹ 27,424 Cr.
Current Price₹ 21,375
Stock P/E55.1
Book Value₹ 1,461
ROCE26.5 %
ROE21.2 %
Dividend Yield0.16 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)78%
Compounded Profit Growth (TTM)278%
Consolidated figures.
Valuation
Market capRs 27,591 Cr
Enterprise valueRs 27,537 Cr
P/E (TTM)55.43x
Price to book14.72x
Price to sales11.63x
EV / EBITDA34.69x
EV / EBIT39.59x
EV / sales11.61x
Price to cash flow79.59x
Earnings yield1.80%
Dividend yield0.16%
P/E, 3-year average42.99x
P/B, 3-year average8.24x
P/E, 5-year average32.76x
P/B, 5-year average5.72x
Profitability
Operating margin (excl. other income)28.66%
Operating margin (incl. other income)29.89%
EBITDA margin33.46%
Pre-tax margin28.22%
Net profit margin20.99%
Net margin, latest quarter23.02%
ROE21.42%
ROCE26.59%
ROA14.25%
ROE, 3-year average22.10%
ROCE, 3-year average27.67%
ROA, 3-year average14.93%
ROE, 5-year average18.40%
ROCE, 5-year average22.62%
ROA, 5-year average12.11%
ROIC (approx.)28.44%
Tax rate25.56%
Other income / net worth1.33%
Growth
Sales growth (latest year)36.98%
Profit growth (latest year)39.94%
Sales CAGR, 3 years19.31%
Sales CAGR, 5 years16.64%
Profit CAGR, 3 years30.57%
Profit CAGR, 5 years35.18%
Sales growth QoQ-17.35%
Profit growth QoQ-30.56%
Sales growth YoY (latest quarter)119.16%
Profit growth YoY (latest quarter)962.37%
Per share
EPS (TTM)Rs 387.97
EPS (latest year)Rs 283.71
EPS (latest quarter)Rs 115.10
EPS, 3-year averageRs 240.11
EPS, 5-year averageRs 179.51
Book value per shareRs 1,461.02
Sales per shareRs 1,848.66
Cash flow per shareRs 270.21
Free cash flow per shareRs -38.97
Dividend per share (latest year)Rs 34.19
Dividend per share, 3-year averageRs 20.11
Dividend per share, 5-year averageRs 15.08
Dividends
Dividend payout12.05%
Dividend payout, 3-year average8.01%
Dividend payout, 5-year average8.40%
Efficiency
Asset turnover0.69x
Fixed asset turnover1.72x
Inventory turnover1.86x
Inventory days197 days
Debtor days98 days
Debtors turnover3.74x
Creditor days129 days
Cash conversion cycle214 days
Working capital days75 days
Leverage
Total debtRs 301 Cr
Cash and bankRs 355 Cr
Net debtRs -54 Cr
Debt to equity0.16x
Net debt / EBITDA-0.07x
Interest coverage26.41x
Current ratio (filing 2026-03-31)2.09x
Quick ratio (filing 2026-03-31)1.37x
Trade payables (filing 2026-03-31)Rs 269 Cr
Owners' fund to total sources63.97%
Debt to assets10.28%
Cash flow
Cash from Operating Activity (latest year)Rs 347 Cr
Cash from Investing Activity (latest year)Rs -423 Cr
Cash from Financing Activity (latest year)Rs 21 Cr
Net Cash Flow (latest year)Rs -55 Cr
Free cash flow (latest year)Rs -50 Cr
FCFE (approx.: FCF + change in debt)Rs 94 Cr
Cash from ops / profit, 5 years1.06x
Sales to cash flow5.84x
Statement figures
Net sales (TTM)Rs 2,372 Cr
Net sales (latest year)Rs 2,023 Cr
Sales (latest quarter)Rs 642 Cr
Operating profit excl. other income (latest year)Rs 580 Cr
Operating profit (latest quarter)Rs 223 Cr
Other income (TTM)Rs 31 Cr
EBITDA (TTM)Rs 794 Cr
PBDT (TTM)Rs 767 Cr
Profit before tax (TTM)Rs 669 Cr
Tax (latest year)Rs 125 Cr
Net profit (TTM)Rs 498 Cr
Net profit (latest year)Rs 364 Cr
Net profit (latest quarter)Rs 148 Cr
Depreciation (TTM)Rs 98 Cr
Depreciation (latest quarter)Rs 27 Cr
Interest (TTM)Rs 26 Cr
Cost of goods sold (latest year)Rs 947 Cr
Total expenditure (latest year)Rs 1,443 Cr
Total income (latest year)Rs 2,048 Cr
Share capitalRs 13 Cr
ReservesRs 1,862 Cr
Shareholders' fundsRs 1,874 Cr
Total assetsRs 2,930 Cr
Net blockRs 1,177 Cr
Capital work in progressRs 211 Cr
InvestmentsRs 2 Cr
ReceivablesRs 541 Cr
InventoryRs 510 Cr
Other liabilitiesRs 754 Cr
Shares outstanding (crore)1.28
Ownership
Promoter holding32.62% (-0.05 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 55.4 is at the 61th percentile of its own 9.4-year range (median 45.4, low 16.4, high 199.6).
P/B 14.72 is at the 97th percentile (median 2.66).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodNEULANDLABNifty 50Difference
1 week-1.8%-2.8% +1.0 pts
1 month-6.6%-6.8% +0.2 pts
3 months+13.5%-7.6% +21.1 pts
6 months+78.8%+0.4% +78.4 pts
1 year+45.0%-9.9% +54.9 pts
2 years+73.3%-13.6% +86.9 pts
3 years+483.1%+14.2% +468.9 pts
5 years+1311.2%+27.9% +1283.3 pts
115 mutual fund schemes hold about ₹3,925 Cr. Over three months 38 bought more and 33 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
HDFC Flexi Cap Fund0.52%587 +175%
ICICI Pru Flexi Cap Fund1.81%468 -15%
HSBC Small Cap Fund1.95%372 +2%
Mahindra Manulife Multi Cap Fund4.00%307 +9%
Mahindra Manulife Small Cap Fund4.35%238 +18%
Bajaj Finserv Flexi Cap Fund1.59%130 -30%
HDFC Pharma and Healthcare Fund3.69%122 +11%
Bandhan Small Cap Fund0.36%122 -16%
Mirae Asset Small Cap Fund1.95%112 -16%
ICICI Pru Balanced Advantage Fund(M0.14%104 +5%
HSBC Multi Cap Fund1.31%79 -1%
Edelweiss Small Cap Fund1.02%74 -1%
Sundaram Small Cap Fund1.59%66 -35%
ITI Small Cap Fund1.72%62 +4%
WOC Flexi Cap Fund0.63%57 -2%
Mahindra Manulife Large & Mid Cap Fund1.94%57 +3%
Bajaj Finserv Small Cap Fund1.87%50 -43%
Axis Flexi Cap Fund0.32%44 +4%
Axis Flexi Cap Fund0.32%43 +4%
TRUSTMF Small Cap Fund1.44%41 -1%
PGIM India Flexi Cap Fund0.69%41 -26%
Abakkus Small Cap Fund1.40%39 -24%
WOC Mid Cap Fund0.45%33 -10%
Nippon India Nifty Smallcap 250 Index Fund0.90%32 +5%
Edelweiss Aggressive Hybrid Fund0.72%29 +3%

Red flags

F-score 6 of 8
explainReceivables outrunning sales Receivables grew 71% vs sales +37% in 2026
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2026-03-25Davuluri Saharsh RaoPromotersother96,000Rs 116.12 CrPledge Creation
2026-03-04Davuluri Saharsh RaoPromotersother12,500Gift
2026-03-04Deepthi DavuluriPromoter Groupother12,500Gift
2025-12-17Ms. Kamala Tayaramma KommulaPromoter Groupother6,000-
2025-12-17Mr. Gannabathula Venkata Krishna RPromotersother6,000Gift
2025-09-23Mr.Gannabathula Veeravenkata SatyaPromoter Groupother10,000Gift
2025-09-23Ms. Gannabathula Venkata Vani SrirPromoter Groupother9,000Gift
2025-09-23Mr. Gannabathula Venkata Krishna RPromotersother19,000Gift
2025-02-28Davuluri Ownership TrustPromotersother79,462Gift
2025-02-28Saharsh Rao DavuluriPromotersother79,462Gift
2025-02-25Davuluri Ownership TrustPromotersother3,253,890Gift
2025-02-25Sucheth Rao DavuluriPromotersother79,573Gift
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

Jun 2026
Sales ₹642 Cr +119.1% vs Jun 2025. Net profit ₹148 Cr +957.1%.
Against our estimate for Jun 2026: sales +36.9%, profit +124.0% beat. Our estimate for Sep 2026: sales Rs 822 Cr, profit Rs 172 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-07-24Dividend - Rs 34 Per Share
2025-07-18Dividend - Rs 12 Per Share
2024-07-12Annual General Meeting/Dividend - Rs 14 Per Share
2023-07-11Annual General Meeting/Dividend - Rs 10 Per Share
2022-07-14Annual General Meeting/Dividend - Rs 5 Per Share
2021-06-29 Annual General Meeting/Dividend - Rs 3 Per Share
2020-11-10 Interim Dividend - Rs 2 Per Share
2020-07-02 Annual General Meeting
2020-02-18 Interim Dividend - Rs 2 Per Share
2019-06-27 Annual General Meeting/Dividend - Rs 1.20 Per Share
2018-08-03 Annual General Meeting
2017-12-21 Annual General Meeting (Date Revised)
2016-08-04 Annual General Meeting/ Dividend - Rs 2/- Per Share
2015-08-06Annual General Meeting/Dividend Rs 1.50 Per Share
2014-08-13Rights Issue 4 : 25 @ Premium Rs 194/- Per Equity Share
2014-06-16Annual General Meeting/Final Dividend Rs.1.50 Per Share And Special Dividend Rs.1.50 Per Share
2013-07-24Annual General Meeting And Dividend Rs.1.20 Per Share
2012-08-03Annual General Meeting
2012-03-21Rights 5:12 @ Premium Rs.35/- Per Share
2011-07-29Annual General Meeting
2010-07-22Annual General Meeting
2009-07-13Div. -Rs.3.50/-Per Share
DateTypeWhat it says
2026-09-16Concall / analyst meetIntimation about Schedule of Analyst / Institutional Investor Meeting on September 23 - 25, 2026
2026-09-15Press ReleaseA press release dated September 15, 2026, titled "Press Release".
2026-09-09Concall / analyst meetIntimation about Schedule of Analyst / Institutional Investor Meeting on September 15, 2026 and September 17, 2026
2026-09-07UpdatesDisclosure under Regulation 30 of SEBI Listing Regulations.
2026-08-25Credit RatingCredit Rating
2026-08-14UpdatesIntimation Regarding Completion Of US FDA Inspection.
2026-08-10Concall / analyst meetTranscript of the Earnings Call conducted on August 5, 2026
2026-08-07Concall / analyst meetSchedule of meet
2026-08-05Concall / analyst meetAudio Recording of the Earnings call conducted on August 5, 2026
2026-08-05Capacity additionDisclosure under Regulation 30 of SEBI Listing Regulations - Enhancement of manufacturing capacity
2026-08-05Giving guarantees/indemnity/Disclosure under Regulation 30 of SEBI Listing Regulations - Execution of deed of Corporate Guarantee
2026-08-05Investor PresentationInvestor Presentation
2026-08-05Press ReleaseA press release dated August 05, 2026, titled "Press Release on the Financial Results of the Company for the quarter ended June 30, 2026".
2026-08-05Board meeting outcomeNeuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-04Shareholder meetingProceedings of Annual General Meeting held on August 04, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with...
2026-07-31UpdatesIntimation under Regulation 30 of SEBI Listing Regulations.
2026-07-28Concall / analyst meetSchedule of meet
2026-07-13Credit RatingCredit Rating
2026-07-09UpdatesLetter to the Shareholders of the Company in relation to the Notice of 42nd Annual General Meeting and the Integrated Annual Report of the Company for...
2026-07-09UpdatesBusiness Responsibility and Sustainability Report for FY 2025-26.
2026-07-09Shareholder meetingNotice of Annual General Meeting to be held on August 04, 2026
2026-06-05Concall / analyst meetIntimation about Schedule of Analyst / Institutional Investor Meeting on June 11, 2026
2026-06-03Concall / analyst meetIntimation about Schedule of Analyst / Institutional Investor Meeting on June 8 & 9, 2026
2026-05-31Concall / analyst meetIntimation about Schedule of Analyst / Institutional Investor Meeting on June 5, 2026
2026-05-22Concall / analyst meetSchedule of meet on May 28, 2026
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
High low price variation greater than 100perc in previous 6 monthsScrip PE is greater than 50 (4 trailing quarters)

Quick answers

What is the market cap of Neuland Laboratories Ltd?

Neuland Laboratories Ltd (NEULANDLAB) has a market capitalisation of Rs 27,424 Cr. at the 2026-10-01 close.

What is the P/E ratio of Neuland Laboratories Ltd?

Neuland Laboratories Ltd trades at a P/E of 55.1 on trailing twelve-month profit, at the 2026-10-01 close.

What were Neuland Laboratories Ltd's latest quarterly results?

In the Jun 2026 quarter, Neuland Laboratories Ltd sales was Rs 642 Cr (+119.1% vs Jun 2025) and net profit was Rs 148 Cr.

What is the 52-week high and low of Neuland Laboratories Ltd?

The 52-week high is Rs 24,225.00 and the 52-week low is Rs 11,500.00.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03